A Phase III Randomized, Double Blind, Placebo-controlled, Multicenter, Parallel Group Study to Assess the Efficacy and Safety of Fixed-dose Combination RHB-104 in Subjects with Moderately Active Crohn's Disease

Trial Profile

A Phase III Randomized, Double Blind, Placebo-controlled, Multicenter, Parallel Group Study to Assess the Efficacy and Safety of Fixed-dose Combination RHB-104 in Subjects with Moderately Active Crohn's Disease

Discontinued
Phase of Trial: Phase III

Latest Information Update: 29 Sep 2016

At a glance

  • Drugs Clarithromycin/clofazimine/rifabutin (Primary)
  • Indications Crohn's disease
  • Focus Therapeutic Use
  • Acronyms MAP EU; MAP-EUROPE
  • Sponsors RedHill Biopharma
  • Most Recent Events

    • 22 Sep 2016 Status changed from not yet recruiting to discontinued.
    • 28 Aug 2016 The study has been discontinued in Hungary.
    • 16 Jun 2015 According to a RedHill Biopharma media release, UK MHRA accepted Clinical Trial Application to initiate this second phase III study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top